9 unknown, 8 recruiting, 6 not yet recruiting, 5 completed. 28 Phase 3, 11 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 28 | Unknown 9, Recruiting 8, Not yet recruiting 6, Completed 5 |
| Phase 2 | 11 | Unknown 5, Recruiting 3, Not yet recruiting 2, Completed 1 |
Follow Chemotherapy: new trials by email Literature Review of Chemotherapy trials Research Report on Chemotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Aromatherapy Combined With Standard Antiemetic Therapy vs Standard Therapy Alone for Prevention of CINV in Breast Cancer Patients Receiving Highly Emetogenic Chemotherapy Aromatherapy, Standard triple antiemetic therapy - Breast Cancer, Aromatherapy | Phase 3 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 374 | 2026-08-18 | 2026-08-12 |
| Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer Docetaxel, Oxaliplatin, Leucovorin - Gastric Cancer, Stomach Cancer | Phase 2 / Phase 3 | Recruiting | Ukrainian Society of Clinical Oncology | 150 | 2025-03-25 | 2025-05-06 |
| Efficacy and Safety of AK104 Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer AK104 - Advanced Ovarian Cancer, AK104(PD-1/CTLA-4 Bispecial Antibody) | Phase 3 | Recruiting | Anhui Provincial Hospital | 100 | 2025-03-11 | 2026-10-28 |
| Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer. Radiation Therapy, Chemoradiotherapy, Consolidation Chemotherapy - Rectal Cancer, Total Neoadjuvant Treatment | Phase 2 / Phase 3 | Recruiting | National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos | 400 | 2025-01-06 | 2026-05-11 |
| BuCy Vs. TBICy for Allo-HSCT in T-ALL Patients TBICy, BuCy - T-Cell Lymphocytic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | Phase 3 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 430 | 2024-12-01 | 2024-11-05 |
| Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment Albumin-bound Paclitaxel + Tegafur Gimeracil Oteracil (S-1) + Anlotinib, Oxaliplatin + Leucovorin + Fluorouracil (FOLFOX regimen) - Biliary Tract Cancer, Second Line Treatment | Phase 2 / Phase 3 | Not yet recruiting | Sun Yat-sen University | 206 | 2024-11-25 | 2024-10-29 |
| IC Plus Low-dose Radiation Plus Cadonilimab in LANPC Intensity Modulated Radiation Therapy, Chemotherapy, Immune checkpoint inhibitor - Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor | Phase 3 | Recruiting | Sun Yat-sen University | 380 | 2024-01-10 | 2026-05-11 |
| A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC 5-fu, Lobaplatin, Placebo - Nasopharyngeal Carcinoma, Leucogen | Phase 3 | Not yet recruiting | Sun Yat-sen University | 132 | 2023-04-01 | 2023-03-22 |
| Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy Toripalimab, Tegafur, IMRT - Esophageal Cancer, Radiation Therapy | Phase 2 / Phase 3 | Unknown | Taizhou Hospital | 60 | 2022-07-01 | 2023-04-18 |
| Clinical Outcome of Palliative Surgery After Translational Therapy for Metastatic Gastric Cancer Versus Maintenance Chemotherapy for Metastatic Gastric Cancer Palliative surgery after translational therapy, Chemotheraoy along - Metastatic Gastric Cancer, Surgery | Phase 3 | Not yet recruiting | Fujian Medical University | 120 | 2022-04-01 | 2022-04-01 |
| Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC Toripalimab (anti-programmed death-1 inhibitor), Albumin paclitaxel, Cisplatin - Oral Squamous Cell Carcinoma, Neoadjvant Therapy | Phase 2 / Phase 3 | Recruiting | Shanghai Jiao Tong University School of Medicine | 80 | 2021-10-01 | 2023-11-22 |
| PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT PD-1 Inhibitor Tislelizumab maintenance therapy - Lymphoma, Large B-Cell, Diffuse, Transplantation | Phase 3 | Unknown | Ruijin Hospital | 94 | 2021-07-09 | 2021-11-22 |
| An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC Triprilimab(JS001), Cisplatin, 5-Fluorouracil - Nasopharyngeal Carcinoma, Metastasis | Phase 2 / Phase 3 | Not yet recruiting | Sun Yat-sen University | 622 | 2021-07-01 | 2021-05-18 |
| PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCT PD-1 Inhibitor Tislelizumab maintenance therapy - Lymphoma, Large B-Cell, Diffuse, Transplantation | Phase 3 | Unknown | Ruijin Hospital | 132 | 2021-04-01 | 2021-03-16 |
| Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma Camrelizumab plus chemo-radiotherapy, Chemo-radiotherapy alone - Nasopharyngeal Cancer, Chemotherapy | Phase 3 | Recruiting | Sun Yat-sen University | 388 | 2020-09-01 | 2020-09-28 |
| Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma reduced dosage IMRT, conventional dosage IMRT - Nasopharyngeal Carcinoma, Radiotherapy | Phase 3 | Recruiting | Sun Yat-sen University | 508 | 2020-08-18 | 2020-09-28 |
| Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma Toripalimab plus concurrent chemo-radiotherapy, Concurrent chemo-radiotherapy - Nasopharyngeal Carcinoma, Chemotherapy | Phase 3 | Recruiting | Sun Yat-sen University | 226 | 2020-07-03 | 2020-09-28 |
| Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC) Platinum-Based Drug, Conventional chemotherapy - Ovarian Cancer, Ovarian Neoplasms | Phase 2 / Phase 3 | Unknown | Blokhin's Russian Cancer Research Center | 164 | 2019-09-01 | 2019-08-13 |
| HFSRT With Concurrent TMZ for Large BMs Temozolomide, hypofractionated radiotherapy - Brain Metastases, Chemotherapy | Phase 3 | Unknown | Chinese Academy of Medical Sciences | 224 | 2018-12-03 | 2019-07-23 |
| A Cohort Study of Beta-Glucan or Beta-Glucan Compound in Metastatic Cancers Beta-Glucan, Glutamine, Immunoglobuin - Metastatic Cancer, Chemotherapy | Phase 2 / Phase 3 | Unknown | E-DA Hospital | 90 | 2018-01-04 | 2021-01-25 |
Showing 20 of 28. Sign in to see all of them.
Breast Neoplasms (5) · Nasopharyngeal Carcinoma (5) · Colorectal Neoplasms (3) · Neoplasm Metastasis (3) · Stomach Neoplasms (3) · Lymphoma, Large B-Cell, Diffuse (2) · Neoplasms (2) · Rectal Neoplasms (2) · Anemia (1) · Biliary Tract Neoplasms (1) · Brain Neoplasms (1) · Breast Diseases (1) · Colonic Neoplasms (1) · Cystadenocarcinoma, Serous (1) · Esophageal Neoplasms (1)
Neoplasms (25) · Neoplasms by Site (22) · Neoplasms by Histologic Type (10) · Digestive System Diseases (8) · Digestive System Neoplasms (8) · Head and Neck Neoplasms (8) · Carcinoma (7) · Gastrointestinal Diseases (7) · Neoplasms, Glandular and Epithelial (7) · Gastrointestinal Neoplasms (6) · Nasopharyngeal Diseases (6) · Otorhinolaryngologic Diseases (6) · Otorhinolaryngologic Neoplasms (6) · Pharyngeal Diseases (6) · Pharyngeal Neoplasms (6)
Fluorouracil (6) · Docetaxel (5) · Cisplatin (3) · Epirubicin (3) · Leucovorin (3) · Oxaliplatin (3) · toripalimab (3) · Cyclophosphamide (2) · Doxorubicin (2) · Drug Therapy (2) · Folfox protocol (2) · Gemcitabine (2) · Radiotherapy (2) · S 1 (combination) (2) · Albumin-Bound Paclitaxel (1)
Sun Yat-sen University (8) · Ruijin Hospital (2) · Academisch Ziekenhuis Maastricht (1) · Anhui Provincial Hospital (1) · Blokhin's Russian Cancer Research Center (1) · Chinese Academy of Medical Sciences (1) · E-DA Hospital (1) · Fudan University (1) · Fujian Medical University (1) · GERCOR - Multidisciplinary Oncology Cooperative Group (1) · Institut du Cancer de Montpellier - Val d'Aurelle (1) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1) · National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos (1) · National Taiwan University Hospital (1) · Shanghai Jiao Tong University School of Medicine (1)
China (16) · France (2) · Lithuania (2) · Taiwan (2) · Netherlands (1) · Russia (1) · Singapore (1) · Ukraine (1)
Audrius Dulskas, PhD (1) · Chiun-Sheng Hunag, MD,PhD (1) · Chong Zhao, MD, PhD (1) · Huilian Zhu, MD (1) · Jianping Xiao, Dr (1) · Mohamed Hebbar, MD (1) · Mykyta Pepenin, MD (1) · Vivianne CG Tjan-Heijnen, MD PhD (1) · Weili Zhao, doctor (1) · Yen-Shen Lu, M.D., Ph.D. (1)
PMID 23955585, PMID 24166522, PMID 25403578, PMID 27310205, PMID 41667193